Erectile Dysfunction, Multiple Sclerosis, Testosterone Deficiency
Conditions
Keywords
Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency
Brief summary
The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samples and a rectal exam in volunteers 55 years and older.
Detailed description
Volunteers will be treated weekly with Xyosted 75 mg (given subcutaneously) for 3 months during which they will have 3 study visits, 6 weeks apart. The Baseline visit will include providing a blood sample, completing questionnaires, receiving training on the Xyosted auto-injector, and undergoing a rectal exam for participants 55 years and older. Visits 2 and 3 will also include collecting a blood sample and completing questionnaires. At Visit 3, the rectal exam for those age 55 years and older will be repeated.
Interventions
DRUGXYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Self injection testosterone treatment
Sponsors
Louisiana State University Health Sciences Center in New Orleans
Antares Pharma Inc.
Tulane University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single open label
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males, age 18 years and older, with a definite diagnosis of multiple sclerosis. * Low testosterone (\<300 ng/dl) on two successive blood draws before 9:00 am * Not in an intercurrent relapse. * Sexually active. * Have subjective complaints about erectile function and libido. * Must be willing and able to get labs drawn, complete questionnaires (BDI, MFIS, MSNQ, SDMT, MSQOL, ADAM, AUASS, SHIM, MSHQ, ICIQ, UDI, IIQ, MPQ) and commit to site visits schedule.
Exclusion criteria
* Males unable to fulfill the above criteria and all female patients. * Males who have been on sex hormone treatment including androgens, estrogens, or anti-estrogens for hypogonadism or other medical condition during the 12 months prior to study. * Males who have taken dehydroepiandrosterone (DHEA) during the 3 months prior to study. * Patients who are taking anticoagulants or have thrombosis, serious cardiac, pulmonary, renal, gastrointestinal, hepatic, immunologic, infectious, neoplastic (with particular focus on patients with known or suspected estrogen or testosterone-dependent tumors), urologic disease especially prostatic hypertrophy/nodules and testicular mass, or insulin-dependent diabetes. * Patients with an abnormal prostate as evidenced by known history of prostatic disease, symptoms suggestive of prostatic disease or elevated levels of prostatic specific antigen (PSA 4 ng/ml or higher) measured within the last 12 months. * Patients with history or complaint of testicular mass. * Patients with hematocrit greater than 50% * Patients with major psychiatric illness * Patients with active alcoholism. * Patients with a history of drug abuse within the past five years. * Patients with BMI ≥ 35 * Patients with generalized skin disease that may affect absorption of testosterone (e.g. psoriasis) or a known skin intolerance to alcohol. * Patients with history of pituitary disease. * Patients with a cholesterol level greater than 300 mg/dl. * Patients who are receiving or have received experimental therapies in the six months preceding enrollment. * Patients who have history of positive titers to Human Immunodeficiency Virus (HIV)1 and 2; HTLV1; or Venereal Disease Research Laboratory (VDRL). * Patients who have clinical evidence of Lyme disease. * Males who are trying to get their partner pregnant. * Patients on Finasteride * Patients who are mentally or emotionally incompetent in the opinion of the examining neurologist or unable to give informed consent, or to understand and comply with the study protocol. * Any other contraindications according to the manufacturer's
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Androgen Deficiency in the Aging Male (ADAM score). | Change from baseline to 12 weeks | Androgen Deficiency in the Aging Male (ADAM score) includes ten Yes or No questions, with an answer Yes to number 1 or 7 or if you answer Yes to more than 3 questions, you may have low Testosterone. |
| Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Sexual Health in Men (SHIM score). | Change from baseline to 12 weeks | Sexual Health in Men (SHIM score) with a range of 1 to 25 with a higher number representing less erectile dysfunction. |
| Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Male Sexual Health Questionnaire short form (MSHQ-SF). | Change from baseline to 12 weeks | Male Sexual Health Questionnaire short form (MSHQ-SF) with a range of 1 to 15 with a higher number representing better ejaculatory function, in addition to one bother/satisfaction question, scored 1 to 5 where the higher represents more bothersome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ). | Change from baseline to 12 weeks | Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) with a range of 0 to 30 with a higher number representing worse cognitive function. |
| Measure the change in self-reported overall quality of life from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Multiple Sclerosis Quality of Life Scale (MSQOL-54). | Change from baseline to 12 weeks | Multiple Sclerosis Quality of Life Scale (MSQOL-54) which goes from 0 to 100 with a higher score indicating a better quality of life. |
| Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the American Urological Association Symptom Score (AUASS). | Change from baseline to 12 weeks | The American Urological Association Symptom Score (AUASS) with a range of 0 to 35 with a higher number representing more severe enlarged prostate symptoms. |
| Measure the change in self-reported urinary incontinence after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using International Consultation on Incontinence Questionnaire short form (ICIQ-SF). | Change from baseline to 12 weeks | International Consultation on Incontinence Questionnaire short form (ICIQ-SF) with a range of 0 to 21 with a higher number representing greater impairment from incontinence. |
| Measure the change in self-reported fatigue from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Modified Fatigue Impact Scale (MFIS). | Change from baseline to 12 weeks | Modified Fatigue Impact Scale (MFIS) with a range of 0 to 84 with a higher number representing greater impact of fatigue on a person's activities. |
| Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Incontinence Impact Questionnaire short form (IIQ-7). | Change from baseline to 12 weeks | Incontinence Impact Questionnaire short form (IIQ-7) with a range of 0 to 100 with a higher number representing greater impact by urinary incontinence on the person's life. |
| Measure the change in self-reported pain from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the McGill Pain Questionnaire (MPQ). | Change from baseline to 12 weeks | McGill Pain Questionnaire (MPQ) with a range of 0 to 78 with a higher number representing greater pain. |
| Measure the change in Multiple Sclerosis lesions, indirectly from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the serum levels of neurofilament-light chains (NF-L). | Change from baseline to 12 weeks | The serum levels of neurofilament-light chains (NF-L) with a higher level representing more neuro-axonal injury in the central nervous system. |
| Measure the change in self-reported urinary incontinence from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Urogenital Distress Inventory short form (UDI-6). | Change from baseline to 12 weeks | Urogenital Distress Inventory short form (UDI-6) with a range of 0 to 100 with a higher number representing higher the disability. |
| Measure the change in self-reported depression from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Beck Depression Inventory (BDI). | Change from baseline to 12 weeks | Beck Depression Inventory (BDI) with a range of 0 to 63 with a higher number representing higher level of depression. |
| Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Symbol Digit Modalities Test (SDMT). | Change from baseline to 12 weeks | Symbol Digit Modalities Test (SDMT) which provides a score for as many items as can be completed in 90 seconds (t-score calculated using age, sex and education normative data), with a higher score representing a better performance. |
Countries
United States
Contacts
Primary ContactMichael Soliman, MD
Backup ContactJesus Lovera, MD
Outcome results
None listed